Allovir Inc

NASDAQ:ALVRUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Contact Information

Headquarters

1100 Winter StreetWALTHAM, MA, United States 02451

Phone

617-433-2605

Fax

302-655-5049

Executives

Executive Chairman of the Board

David Hallal

President, Chief Financial Officer, Director

Vikas Sinha

Chief Executive Officer, Director

Diana Brainard

Co-Founder, Chief Scientific Officer

Ann Leen

Chief Accounting Officer

Brett Hagen